Eversept Partners, LP Xenon Pharmaceuticals Inc. Transaction History

Eversept Partners, LP

$1.26 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Nov 08, 2023	SELL	$34.84 - $43.54 $1.11 Million - $1.39 Million	-31,894 Reduced 15.69%	171,378 $6.6 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $1.11 Million - $1.39 Million	-31,894 Reduced 15.69%	171,378 $6.6 Million
Q1 2023 Nov 08, 2023	SELL	$33.46 - $40.35 $2.42 Million - $2.92 Million	-72,432 Reduced 26.27%	203,272 $7.28 Million
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $2.42 Million - $2.92 Million	-72,432 Reduced 26.27%	203,272 $7.28 Million
Q4 2022 Nov 08, 2023	BUY	$33.06 - $39.43 $532,001 - $634,507	16,092 Added 6.2%	275,704 $10.9 Million
Q4 2022 Feb 14, 2023	BUY	$33.06 - $39.43 $532,001 - $634,507	16,092 Added 6.2%	275,704 $10.9 Million
Q3 2022 Nov 08, 2023	SELL	$30.79 - $39.82 $6.35 Million - $8.21 Million	-206,299 Reduced 44.28%	259,612 $9.37 Million
Q3 2022 Nov 14, 2022	SELL	$30.79 - $39.82 $6.35 Million - $8.21 Million	-206,299 Reduced 44.28%	259,612 $9.37 Million
Q2 2022 Nov 08, 2023	BUY	$25.44 - $35.16 $1.42 Million - $1.97 Million	55,890 Added 13.63%	465,911 $14.2 Million
Q2 2022 Aug 15, 2022	BUY	$25.44 - $35.16 $1.42 Million - $1.97 Million	55,890 Added 13.63%	465,911 $14.2 Million
Q1 2022 Nov 08, 2023	BUY	$25.09 - $33.13 $5.99 Million - $7.91 Million	238,643 Added 139.25%	410,021 $12.5 Million
Q1 2022 May 16, 2022	BUY	$25.09 - $33.13 $5.03 Million - $6.64 Million	200,502 Added 95.7%	410,021 $12.5 Million
Q4 2021 Nov 08, 2023	BUY	$15.6 - $35.4 $594,999 - $1.35 Million	38,141 Added 22.26%	209,519 $6.55 Million
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $3.27 Million - $7.42 Million	209,519 New	209,519 $6.55 Million
Q2 2020 Aug 13, 2020	SELL	$10.21 - $14.9 $730,944 - $1.07 Million	-71,591 Closed	0 $0
Q1 2020 Nov 08, 2023	SELL	$8.08 - $17.57 $1.16 Million - $2.53 Million	-144,018 Reduced 66.8%	71,591 $811,000
Q1 2020 May 13, 2020	SELL	$8.08 - $17.57 $1.16 Million - $2.53 Million	-144,018 Reduced 66.8%	71,591 $812,000
Q3 2019 Nov 08, 2023	SELL	$8.74 - $10.51 $76,308 - $91,762	-8,731 Reduced 3.89%	215,609 $1.94 Million
Q3 2019 Nov 13, 2019	SELL	$8.74 - $10.51 $76,308 - $91,762	-8,731 Reduced 3.89%	215,609 $1.94 Million
Q1 2019 Nov 08, 2023	BUY	$6.39 - $10.42 $122,918 - $200,439	19,236 Added 9.38%	224,340 $2.28 Million
Q1 2019 May 14, 2019	BUY	$6.39 - $10.42 $122,918 - $200,439	19,236 Added 9.38%	224,340 $2.28 Million
Q4 2018 Nov 08, 2023	SELL	$5.61 - $12.62 $26,002 - $58,493	-4,635 Reduced 2.21%	205,104 $1.29 Million
Q4 2018 Feb 13, 2019	SELL	$5.61 - $12.62 $26,002 - $58,493	-4,635 Reduced 2.21%	205,104 $1.29 Million
Q3 2018 Nov 08, 2023	BUY	$9.0 - $14.9 $345,249 - $571,578	38,361 Added 22.38%	209,739 $2.77 Million
Q3 2018 Nov 14, 2018	BUY	$9.0 - $14.9 $1.89 Million - $3.13 Million	209,739 New	209,739 $2.77 Million

Others Institutions Holding XENE

# of Institutions

212

Shares Held

70.2M

Call Options Held

88.3K

Put Options Held

28.8K

Avoro Capital Advisors LLC New York, NY

5.67M
Shares

$217 Million
3.36% of portfolio
Driehaus Capital Management LLC Chicago, IL

4.6M
Shares

$176 Million
1.77% of portfolio
Wellington Management Group LLP Boston, MA

3.84M
Shares

$147 Million
0.03% of portfolio
Braidwell LP Stamford, CT

2.71M
Shares

$104 Million
3.02% of portfolio
Commodore Capital LP New York, NY

2.7M
Shares

$103 Million
9.03% of portfolio

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Account